Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
166 hedge funds and large institutions have $1.28B invested in Day One Biopharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 68 increasing their positions, 36 reducing their positions, and 23 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 36
48% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 23
25% more capital invested
Capital invested by funds: $1.03B → $1.28B (+$254M)
19.4% more ownership
Funds ownership: 85.48% → 104.89% (+19%)
6% more funds holding
Funds holding: 156 → 166 (+10)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
48% less call options, than puts
Call options by funds: $2.17M | Put options by funds: $4.16M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$67.8M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$44.3M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$26.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$10.7M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$7.39M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.48M |
| 4 |
DM
Deerfield Management
New York
|
-$4.36M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.82M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
176
Aigen Investment Management
New York
| – | -$193K | -14,008 | Closed |
|
|
YIH
177
Y-Intercept (HK)
Hong Kong
| – | -$190K | -13,822 | Closed |
|
|
TC
178
Torno Capital
Cohasset,
Massachusetts
| – | -$180K | -13,037 | Closed |
|
179
HSBC Holdings
London,
United Kingdom
| – | -$163K | -11,658 | Closed |
|
|
CC
180
Centiva Capital
New York
| – | -$143K | -10,366 | Closed |
|
|
PP
181
Paloma Partners
Greenwich,
Connecticut
| – | -$138K | -10,000 | Closed |
|
|
RCM
182
Regency Capital Management
Honolulu,
Hawaii
| – | -$138K | -10,000 | Closed |
|
183
SG Americas Securities
New York
| – | -$113K | -8,222 | Closed |
|
184
Group One Trading
Chicago,
Illinois
| – | -$85.4K | -5,987 | Closed |
|
|
CFM
185
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$16.5K | -1,200 | Closed |
|
186
Pacer Advisors
Malvern,
Pennsylvania
| – | -$11.7K | -851 | Closed |
|
|
CWM
187
CarsonAllaria Wealth Management
Glen Carbon,
Illinois
| – | -$2.48K | -180 | Closed |
|
|
SAM
188
Smartleaf Asset Management
Boston,
Massachusetts
| – | -$262 | -19 | Closed |
|
DAWN Hedge Fund Activity: Q3 2024 in Review
166 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q3 2024, worth a combined $1.28B — up 25% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new DAWN positions and 23 closed out — a net gain of 11 holders — while 68 added to existing stakes and 36 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $67.8M. The largest seller was Polar Capital Holdings, cutting an estimated $10.7M.
- 166 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q3 2024, up from 156 in Q2 2024.
- Funds reported $1.28B of Day One Biopharmaceuticals stock for Q3 2024, up 25% quarter-over-quarter.
- 34 funds opened new Day One Biopharmaceuticals positions in Q3 2024 and 23 closed out, a net change of +11 holders.
- The largest Day One Biopharmaceuticals buyer in Q3 2024 was Fidelity Investments, an estimated $67.8M added.
- The largest Day One Biopharmaceuticals seller in Q3 2024 was Polar Capital Holdings, an estimated $10.7M sold.
Based on aggregated 13F filings for Q3 2024.